0001562180-19-005195.txt : 20191018 0001562180-19-005195.hdr.sgml : 20191018 20191018171344 ACCESSION NUMBER: 0001562180-19-005195 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191016 FILED AS OF DATE: 20191018 DATE AS OF CHANGE: 20191018 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Truitt Joseph CENTRAL INDEX KEY: 0001452429 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33095 FILM NUMBER: 191158395 MAIL ADDRESS: STREET 1: C/O ACHILLION PHARMACEUTICALS, INC. STREET 2: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACHILLION PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070336 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 BUSINESS PHONE: 203-624-7000 MAIL ADDRESS: STREET 1: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2019-10-16 false 0001070336 ACHILLION PHARMACEUTICALS INC ACHN 0001452429 Truitt Joseph C/O ACHILLION PHARMACEUTICALS, INC. 1777 SENTRY PARKWAY W, BLDG 14, STE 200 BLUE BELL PA 19422 true true false false Chief Executive Officer Common Stock 2019-10-16 4 M false 100234.00 3.10 A 103734.00 D Common Stock 2019-10-16 4 M false 33250.00 3.28 A 136984.00 D Common Stock 2019-10-16 4 S false 100234.00 6.3749 D 36750.00 D Common Stock 2019-10-16 4 S false 33250.00 6.3749 D 3500.00 D Stock Option (Right to Buy) 3.28 2019-10-16 4 M false 33250.00 0.00 D 2019-12-18 Common Stock 33250.00 0.00 D Stock Option (Right to Buy) 3.10 2019-10-16 4 M false 100234.00 0.00 D 2020-12-16 Common Stock 100234.00 87766.00 D This option was granted on December 18, 2009 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter. This option was granted on December 16, 2010 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter. The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Truitt on March 8, 2018. /s/ Joseph Truitt 2019-10-18